Restricted accessResearch articleFirst published online 2021-04
Trends in the Incidence and Antibiotic Resistance of Enterococcal Bloodstream Isolates: A 7-Year Retrospective Multicenter Epidemiological Study in Italy
The spread of resistance to vancomycin and other last-resort drugs in Enterococcus spp. remains of concern. In Italy, surveillance data for enterococcal bloodstream isolates in humans are scant. The aim of our study was to assess the incidence trends of bacteremias due to Enterococcus species and their prevalence trends of antimicrobial resistance. We retrospectively included all consecutive not-duplicate Enterococcus species isolated from blood cultures, in patients from 11 Italian hospitals (2011–2017). Incidence was defined as the number of isolates per 10,000 patient-days, while resistance prevalence was defined as the number of resistant strains divided by the number of tested strains. We included 4,858 isolates (59%, 36%, and 5% due to Enterococcus faecalis, E. faecium, and other Enterococcus spp., respectively). Over the study period, the incidence of bacteremias due to E. faecalis (incidence rate ratio [IRR]: 1.02, 95% confidence interval [CI]: 1.00–1.04, p = 0.008) and E. faecium increased (IRR: 1.03, 95% CI: 1.01–1.05, p < 0.001) alongside with the whole enterococcal bacteremias trend (IRR: 1.02, 95% CIs: 1.01–1.04, p = 0.002). A progressive increase in vancomycin-resistant E. faecium (VREfm) bacteremias was observed. Resistance to tigecycline and linezolid was rarely reported. The incidence of enterococcal bloodstream isolates is increasing in Italy, together with the prevalence of VREfm. Resistance to linezolid, a cornerstone drug used in the treatment of VRE bloodstream infection, remains negligible.
Get full access to this article
View all access options for this article.
References
1.
WeinerL.M., WebbA.K, LimbagoB., DudeckM.A, PatelJ., KallenA.J, EdwardsJ.R, and SievertD.M.. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect. Control Hosp. Epidemiol. 37:1288–1301.
2.
European Centre for Disease Prevention and Control. 2013. Point Prevalence Survey of Healthcare Associated Infections and Antimicrobial Use in European Acute Care Hospitals. ECDC, Stockholm.
SuppliM., AabenhusR., HarboeZ.B, AndersenL.P, TvedeM., and JensenJ.-U.S. 2011. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin. Microbiol. Infect. 17:1078–1083.
5.
EdmondM.B., OberJ.F, DawsonJ.D, WeinbaumD.L, and WenzelR.P.. 1996. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin. Infect. Dis. 23:1234–1239.
6.
AyobamiO., WillrichN., ReussA., EckmannsT., and MarkwartR.. 2020. The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg. Microbes Infect. 9:1180–1193.
7.
Jabbari ShiadehS.M., PormohammadA., HashemiA., and LakP.. 2019. Global prevalence of antibiotic resistance in blood-isolated Enterococcus faecalis and Enterococcus faecium: a systematic review and meta-analysis. Infect. Drug Resist. 12:2713–2725.
8.
MendesR.E., SaderH.S, CastanheiraM., and FlammR.K.. 2018. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity. J. Chemother. 30:280–289.
9.
HuangL., ZhangR., HuY., ZhouH., CaoJ., LvH., ChenS., DingS., and ChenG.. 2019. Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017. Antimicrob. Resist. Infect. Control, 8:90.
10.
HuF., ZhuD., WangF., and WangM.. 2018. Current status and trends of antibacterial resistance in China. Clin. Infect. Dis. 67:S128–S134.
TrecarichiE.M., PaganoL., CandoniA., PastoreD., CattaneoC., FanciR., NosariA., CairaM., SpadeaA., BuscaA., VianelliN., TumbarelloM., and HeMABIS Registry—SEIFEM Group, Italy. 2015. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin. Microbiol. Infect. 21:337–343.
13.
TuranoA., RavizzolaG., PeroniL., CerutiT., GrecoL.M, PitzusE., SantiniG., CrestiS., and SattaG.. 1994. A multicentre study: staphylococcus and Enterococcus susceptibility to antibiotics. Eur. J. Epidemiol. 10:567–572.
14.
EspositoS., GioiaR., De SimoneG., NovielloS., LombardiD., Di CrescenzoV.G, FilippelliA., RegaM.R, MassariA., ElbertiM.G, GrisiL., BocciaG., De CaroF., and LeoneS.. 2015. Bacterial epidemiology and antimicrobial resistance in the surgery wards of a large teaching hospital in Southern Italy. Mediterr. J. Hematol. Infect. Dis. 7:e2015040.
15.
FontanaR., LigozziM., MazzariolA., VeneriG., and CornagliaG.. 1998. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance. Clin. Infect. Dis. 27,(Suppl. 1)::S84–S86.
16.
ManciniA., VerdiniD., La VignaG., RecanatiniC., LombardiF.E, and BarocciS.. 2016. Retrospective analysis of nosocomial infections in an Italian tertiary care hospital. New Microbiol. 39:197–205.
17.
AznarJ., LepeJ.A, and DowzickyM.J.. 2012. Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance, Study, 2004–2009). J. Chemother. 24:74–80.
18.
ManfrediR., NanettiA., ValentiniR., MorelliS., and CalzaL.. 2004. A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of enterococci in a large Italian Teaching Hospital. Infect. Dis. Clin. Pract. 12:163–170.
19.
PesceA., DebbiaE.A, ToniM., and SchitoG.C.. 1992. Antibiotic resistance of clinical isolates of enterococcus in Italy. Clin. Infect. Dis. 15:490–494.
20.
DicuonzoG., GherardiG., LorinoG., AngelettiS., BattistoniF., BertucciniL., CretiR., Di RosaR., VendittiM., and BaldassarriL.. 2001. Antibiotic resistance and genotypic characterization by PFGE of clinical and environmental isolates of enterococci. FEMS Microbiol. Lett. 201:205–211.
21.
Del GrossoM., KärkiT., D'AnconaF.P, and PantostiA.. 2015. Decrease of vancomycin resistance in Enterococcus faecium isolates from bloodstream infections in Italy from 2003 to 2013. Antimicrob. Agents Chemother. 59:3690–3691.
22.
European Centre for Disease Prevention and Control. 2017. Surveillance of antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm.
23.
BenderJ.K., CattoirV., HegstadK., SadowyE., CoqueT.M, WesthH., HammerumA.M, SchafferK., BurnsK., MurchanS., NovaisC., FreitasA.R, PeixeL., Del GrossoM., PantostiA., and WernerG.. 2018. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist. Updat. 40:25–39.
24.
BonoraM.G., SolbiatiM., StepanE., ZorziA., LuzzaniA., CataniaM.R, and FontanaR.. 2006. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J. Clin. Microbiol. 44:1153–1155.
25.
FossatiM., CappelliB., BiralE., ChiesaR., BiffiA., OssiC., MoroM., CirilloD.M, ClementiM., SolimanC., CiceriF., RoncaroloM.G, FumagalliL., and MarktelS.. 2010. Fatal vancomycin- and linezolid-resistant Enterococcus faecium sepsis in a child undergoing allogeneic haematopoietic stem cell transplantation for beta-thalassaemia major. J. Med. Microbiol. 59:839–842.
26.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0; 2019. Available at eucast.org/clinical_breakpoints/ (accessed December20, 2019).
27.
ZhangY., DuM., ChangY., ChenL.-A, and ZhangQ.. 2017. Incidence, clinical characteristics, and outcomes of nosocomial Enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study. Antimicrob. Resist. Infect. Control 6:73.
28.
BuettiN., AtkinsonA., MarschallJ., KronenbergA., and the Swiss Centre for Antibiotic Resistance (ANRESIS). 2017. Incidence of bloodstream infections: a nationwide surveillance of acute care hospitals in Switzerland 2008–2014. BMJ Open, 7:e013665.
29.
European Centre for Disease Prevention and Control. 2018. Surveillance of antimicrobial resistance in Europe—Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. ECDC, Stockholm.
30.
MillerW.R., MurrayB.E, RiceL.B, and AriasC.A.. 2016. Vancomycin-resistant enterococci: therapeutic challenges in the 21st century. Infect. Dis. Clin. North Am. 30:415–439.
31.
ChirurgiV.A., OsterS.E, GoldbergA.A, ZervosM.J, and McCabeR.E. 1991. Ampicillin-resistant Enterococcus raffinosus in an acute-care hospital: case-control study and antimicrobial susceptibilities. J. Clin. Microbiol. 29:2663–2665.
32.
MonticelliJ., KnezevichA., LuzzatiR., and Di BellaS.. 2018. Clinical management of non-faecium non-faecalis vancomycin-resistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus casseliflavus/flavescens. J. Infect. Chemother. 24:237–246.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
